Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor

NCT05895825 is registered in ClinicalTrials.gov with Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT05895825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05895825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor
Lead sponsor
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
July 26, 2023
Completion date
September 30, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor